Lilly(Eli) & Co

NYSE:LLY

298.85

+12.58 (+4.39%)

4:04:08 PM EDT: $298.85 0.00 (0.00%)

Products

FDA Approves Lilly's Mounjaro™ (Tirzepatide) Injection, The First And Only Gip And Glp-1 Receptor Agonist For The Treatment Of Adults With Type 2 Diabetes

Published: 05/13/2022 22:07 GMT

Lilly(Eli) & Co (LLY) - FDA Approves Lilly's Mounjaro™ (tirzepatide) Injection, the First and Only Gip and Glp-1 Receptor Agonist for the Treatment of Adults With Type 2 Diabetes.
Eli Lilly - Mounjaro is Expected to Be Available in United States in Coming Weeks.